| Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function | 1991/07/01 | English | 205 |
| Cardiovascular System Effects of Marijuana | 2002/11/01 | English | 197 |
| Origin and Uses of Primum Non Nocere—Above All, Do No Harm! | 2005/04/01 | English | 197 |
| Efficacy of Antidepressants as Analgesics: A Review | 2012/01/01 | English | 189 |
| Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir | 1998/02/01 | English | 188 |
| Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis | 2007/12/01 | English | 188 |
| Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study | 1993/03/01 | English | 188 |
| Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects | 2006/05/01 | English | 188 |
| Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review | 2008/01/01 | English | 185 |
| Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers | 2007/04/01 | English | 184 |
| Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects | 2002/10/01 | | 181 |
| Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities | 2006/02/01 | English | 181 |
| The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective | 2003/05/01 | English | 180 |
| Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System | 2001/06/01 | English | 176 |
| Hawthorn | 2002/06/01 | English | 168 |
| RadixPuerariae: An overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use | 2013/05/16 | English | 166 |
| Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension | 2008/05/01 | English | 165 |
| Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans | 2010/08/01 | English | 162 |
| Analgesic Effect of Delta‐9‐Tetrahydrocannabinol | 1975/02/03 | English | 157 |
| Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration | 1997/05/01 | English | 157 |
| Hypnotic and Antiepileptic Effects of Cannabidiol | 1981/08/09 | English | 157 |
| Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial | 2005/07/01 | English | 157 |
| Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms | 2004/10/01 | English | 156 |
| Pharmacokinetics of Pregabalin in Subjects with Various Degrees of Renal Function | 2003/03/01 | English | 156 |
| Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents | 1996/09/01 | English | 156 |
| The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers | 2014/11/12 | English | 155 |
| Microbial Biofilms: Their Development and Significance for Medical Device—Related Infections | 1999/09/01 | English | 155 |
| Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem | 2003/10/01 | English | 154 |
| Developmental Changes in Pharmacokinetics and Pharmacodynamics | 2018/09/24 | English | 153 |
| CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole | 2009/02/01 | English | 152 |